Palbociclib OverviewPalbociclib (codenamed PD-0332991, trade name Ibrance) is a drug for the treatment of HR-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy. Contents 1 Mechanism of action 2 Administration 3 Approvals and indications 3.1 HR+ breast cancer 4 Mechanisms of Resistance 4....
Read more Palbociclib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palbociclib
Recent Palbociclib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg, 125mg, 75mg
- Tablet: 100mg, 125mg, 75mg
Other drugs which contain Palbociclib or a similar ingredient: (1 result)
- IBRANCE Palbociclib